Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The company is investing ₹3,000 crore in expanding capacities, particularly for high-value CDMO services, which are projected to double their revenue share by 2030. Analysts are optimistic, raising earnings forecasts and maintaining a 'BUY' rating, anticipating continued growth across its diverse segments.
Laurus Labs' stock has surged 30% following robust FY26 results, driven by strong growth in its contract manufacturing business and an improved product mix. The company is investing ₹3,000 crore to expand capacities, particularly in high-value CDMO services, aiming to double…
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.